&nbsp;

dapProstateJuly18.xml

Jul 2018

Document

dapProstateJuly18.html

Jul 2018

Regimen

NIVL+IPIL

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma

New Drug Funding Program

Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Nov 2024

Regimen

NIVL(MNT)

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma

Drugs Used:

nivolumab

Quick Link(s):

Regimen Monograph

Regimen

DURV

Cancer Type:

Lung,

Non-Small Cell

Intent: Curative

Funding:

New Drug Funding Program

Durvalumab - Locally Advanced Unresectable Stage III Non-Small Cell Lung Cancer Following Concurrent Chemoradiation

Drugs Used:

durvalumab

Quick Link(s):

Regimen Monograph

Regimen

NIVL(MNT)

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)

Drugs Used:

nivolumab

Quick Link(s):

Regimen Monograph

Regimen

DENO

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Drugs Used:

denosumab (Unfunded)

Quick Link(s):

Regimen Monograph

Document

Dr. Debra Bournes

Nov 2018

Cancer facts

New cases of intra-oral cancers increasing after decades of decline

Jan 2019

Document

newWindow-icon-LightBlue.png

Jan 2019

Document

newWindowIconLightBlue.png

Jan 2019

Regimen

DABRTRAM

Cancer Type:

Skin,

Melanoma

Intent: Adjuvant, Curative

Funding:

Exceptional Access Program

daBRAfenib - For the adjuvant treatment of resected Stage III cutaneous melanoma, based on criteria

Exceptional Access Program

trametinib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria

Drugs Used:

daBRAFenib,

trametinib